Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Purine SCHEMBL25254163 | 0.80 | KDM4E (0.59) | KDM4ETYRO3DYRK1B | |
| SCHEMBL1551964 | 0.79 | PDK2 (0.36) | KDM4ETYRO3DYRK1BNPC1RAB9A | |
| SCHEMBL15718879 | 0.79 | KDM4E (0.50) | KDM4ETYRO3DYRK1B | |
| SCHEMBL3963582 | 0.79 | KDM4E (0.50) | KDM4ETYRO3DYRK1BCSNK1A1CLK4 | |
| SCHEMBL1551962 | 0.79 | KDM4E (0.50) | KDM4ETYRO3DYRK1BHTT | |
| SCHEMBL369014 | 0.79 | KDM4E (0.50) | KDM4ETYRO3DYRK1B | |
| SCHEMBL15571871 | 0.75 | KDM4E (0.46) | KDM4ETYRO3DYRK1BNPC1RAB9A | |
| SCHEMBL15570735 | 0.72 | KDM4E (0.43) | KDM4ETYRO3DYRK1B | |
| SCHEMBL2885131 | 0.72 | HPGDS (0.41) | NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL4982877 | 0.71 | METAP2 (0.46) | KDM4ENPC1RAB9AHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009097490-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-08-06 | — | — | WO | claimed |
| US-20090192176-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-30 | — | — | US | claimed |
| US-7419965-B2 | Nucleotide lipid ester derivatives | HEIDELBERG PHARMA AG (DE) | 2008-09-02 | — | — | US | claimed |
| US-20070112004-A1 | 4'-THIO-L-XYLOY FURANOSYL NUCLEOSIDES, PRECURSORS THEREOF, PREPARATION AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2007-05-17 | — | — | US | claimed |
| US-20060293514-A1 | Nucleotide lipid ester derivatives | HEIDELBERG PHARMA AG (DE) | 2006-12-28 | — | — | US | claimed |
| CN-1771253-A | Nucleotide lipid ester derivatives | HEIDELBERG PHARMA GMBH (DE) | 2006-05-10 | — | — | CN | claimed |
| EP-1606233-A2 | NUCLEOTIDE LIPID ESTER DERIVATIVES | Heidelberg Pharma GmbH (DE) | 2005-12-21 | — | — | EP | claimed |
| US-20050130969-A1 | 4'-Thio-L-xyloy furanosyl nucleosides, precursors thereof, preparation and use thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2005-06-16 | — | — | US | claimed |
| WO-2004083155-A2 | NUCLEOTIDE LIPID ESTER DERIVATIVES | HEIDELBERG PHARMA GMBH (DE) | 2004-09-30 | — | — | WO | claimed |
| EP-1172365-B1 | Process for preparing 2,6-dichloropurine | SUMIKA FINE CHEMICALS CO LTD (JP) | 2004-03-17 | — | — | EP | claimed |
| US-20030144235-A1 | Anticarcinogenic agents for treating cancer, a viricides for viral diseases, inhibit DNA replication | SOUTHERN RESEARCH INSTITUTE | 2003-07-31 | — | — | US | claimed |
| WO-2001066118-A1 | 4'-THIO-L-XYLO FURANOSYL NUCLEOSIDES, PRECURSORS THEREOF, PREPARATION AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2001-09-13 | — | — | WO | claimed |
| US-20250367649-A1 | PHOTOCATALYSTS, PREPARATION AND USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (CA) | 2025-12-04 | — | — | US | disclosed |
| US-12391694-B2 | Process for the preparation of 2-fluoroadenine | MERCK SHARP & DOHME LLC | 2025-08-19 | — | — | US | disclosed |
| WO-2025090871-A1 | ELECTROPHILIC PURINE COMPOUNDS FOR MODIFICATION OF PROTEINS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-05-01 | — | — | WO | disclosed |
| EP-4472962-A1 | PHOTOCATALYSTS, PREPARATION AND USE THEREOF | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2024-12-11 | — | — | EP | disclosed |
| WO-1991004033-A1 | 2'-DEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AND ANTICANCER AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1991-04-04 | — | — | WO | disclosed |
| US-4853386-A | INHIBITORS OF SRS-A(SLOW REACTING SUBSTANCE OF ANAPHYLAXIS) FROM LUNG TISSUES | BOEHRINGER MANNHEIM GMBH (DE) | 1989-08-01 | — | — | US | disclosed |
| EP-0072027-B1 | ANTIVIRAL COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-05-18 | — | — | EP | disclosed |
| EP-0072027-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144235-A1 | Anticarcinogenic agents for treating cancer, a viricides for viral diseases, inhibit DNA replication | POLL, PCNA, YWHAZ | KDM4E 1895/4885TYRO3 1599/4885DYRK1B 3425/4885 |
| US-20090192176-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3CD | KDM4E 1603/4885TYRO3 716/4885DYRK1B 977/4885 |
| US-20060293514-A1 | Nucleotide lipid ester derivatives | NTPCR, ABHD16A, ABCB4 | KDM4E 2235/4885TYRO3 3878/4885DYRK1B 4717/4885 |
| US-20070112004-A1 | 4'-THIO-L-XYLOY FURANOSYL NUCLEOSIDES, PRECURSORS THEREOF, PREPARATION AND USE THEREOF | POLL, PNP, UNG | KDM4E 1089/4885TYRO3 1037/4885DYRK1B 2234/4885 |
| US-20250367649-A1 | PHOTOCATALYSTS, PREPARATION AND USE THEREOF | PPOX, AOX1, CYP3A7 | KDM4E 1365/4885TYRO3 283/4885DYRK1B 4185/4885 |
| US-20050130969-A1 | 4'-Thio-L-xyloy furanosyl nucleosides, precursors thereof, preparation and use thereof | POLL, PNP, UNG | KDM4E 1089/4885TYRO3 1037/4885DYRK1B 2234/4885 |
| US-12391694-B2 | Process for the preparation of 2-fluoroadenine | DCTD, AMPD2, CDA | KDM4E 1707/4885TYRO3 4622/4885DYRK1B 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.